Inhaled RORγt drug candidate / Genfit - LARVOL DELTA

GENFIT : THE BIOTECH GENFIT BURIES ITS PROJECT TO TREAT HUMAN FATTY LIVER DISEASE [Google translation] (BFM Bourse) - "After having made investors dream of a potential market of several tens of billions of dollars, the biotech from Lille definitively buries its project...Forced to reduce its expenses, the firm will cut its workforce and open discussions with its creditors....Other programs, including TGFTX1, are also discontinued."

Discontinued • Immunology • Psoriasis